Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, CHINA PHARMA HOLDINGS, INC. reported revenue of $4M, down 8.5% year over year. Operating margin was -78.2% and net margin -76.9%, on a free-cash-flow margin of 2.1% with capital expenditure at 1.4% of revenue. Every figure is computed directly from CPHI's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $4M | -78.2% | -76.9% |
| FY2024 | $5M | -101.3% | -104.6% |
| FY2023 | $7M | -39.2% | -43.9% |
| FY2022 | $8M | -43.8% | -49.0% |
| FY2021 | $10M | -29.7% | -35.3% |
How does CPHI compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.